For the Inventor, By the Inventor

Enter assignee name

Galderma Research & Development

USPTO Granted Patents = 222

CIPO Patents = 10

EPO Patents = 142

Forward Citations = 448

Loading Chart...

Loading Chart...

153 inventors (with patents filed for the assignee):

Laurence Clary (35 out of 37 patents)

Jean-Guy Boiteau (25 out of 34 patents)

Claire Mallard (19 out of 33 patents)

4. Claire Bouix-Peter (18 out of 18 patents)

5. Jean-Claude Pascal (17 out of 24 patents)

6. Etienne Thoreau (17 out of 19 patents)

7. Michael Graeber (17 out of 30 patents)

8. Thibaud Biadatti (16 out of 19 patents)

9. Michel Rivier (15 out of 16 patents)

10. Branislav Musicki (14 out of 14 patents)

11. Pascal Collette (14 out of 14 patents)

12. Janusz Czernielewski (13 out of 15 patents)

13. Jerôme Aubert (12 out of 12 patents)

14. Jean-Michel Bernardon (12 out of 86 patents)

15. Laurent Chantalat (10 out of 18 patents)

Core Competencies:

Photodynamic Treatment

mTOR Inhibitors

Dermatological Compositions

Lipid Microcapsules

Chemical Foams

Retinoid Compounds

Th17 Differentiation Markers

Nanoparticles

Acne Treatments

Inflammatory Skin Disorders

Chemokine Receptor Antagonists

MicroRNAs

222 patents: Sort by Forward Citations

1. 11731973 - Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors (2023-08-22),

2. 11730814 - Pulse photodynamic treatment of photodamaged skin (2023-08-22),

3. 11518767 - MTOR inhibitor compounds (2022-12-06),

4. 11375946 - UV device for smartphone-based evaluation of skin conditions (2022-07-05),

5. 11278548 - Methods and compositions for reducing side effects in chemotherapeutic treatments (2022-03-22),

6. 11235010 - Composition containing lactic acid bacteria and its use to treat atopic dermatitis (2022-02-01),

7. 11234931 - No-rinse chemical foam containing brimonidine, and use thereof in the treatment of rosacea (2022-02-01),

8. 11214655 - Method of crosslinking glycosaminoglycans (2022-01-04),

9. 11197831 - Compositions comprising at least one dispersed active principle and lipid microcapsules (2021-12-14),

10. 11162831 - Device for packaging and dispensing a product, notably a pharmaceutical or cosmetic product (2021-11-02),

11. 11160812 - No-rinse chemical foam containing clobetasol propionate, and use thereof in the treatment of psoriasis (2021-11-02),

12. 11020348 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis (2021-06-01),

13. 11020347 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of acne (2021-06-01),

14. 10995052 - Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof (2021-05-04),

15. 10987307 - No-rinse chemical foam comprising ivermectin (2021-04-27),

Galderma Research & Development, part of Nestlé Skin Health, is a leading global dermatology company dedicated to delivering innovative medical solutions to meet the needs of people throughout their lifetime. With a focus on skin, hair, and nail diseases, Galderma Research & Development works to advance the science of dermatology and create effective and safe treatments for various skin conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

222 Patents

#2 in Biot

#115 in France

#3,738 in the World

Galderma Research & Development

Forward Citations = 448

153 inventors:

Laurence Clary (35 out of 37 patents)

Jean-Guy Boiteau (25 out of 34 patents)

Claire Mallard (19 out of 33 patents)

4. Claire Bouix-Peter (18 out of 18 patents)

5. Jean-Claude Pascal (17 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…